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ALLERGIES AND OTHER REACTIONS




T HE social and economic problems in bringing a drug or cosmetic
to the market place are large and complex.1 A new drug may take
several years and millions of dollars to develop. The economic health
of one or more drug companies may be involved, as well as the
economic welfare of their employees. The drug may bring materially
improved health or well-being to a sizeable segment of the popula-
tion, and it may even save or prolong their lives if it performs as ex-
pected; conversely, the drug may cause harm to the public and the
drug house alike if it performs in a manner other than that antici-
pated.
No drug or cosmetic is, or ever will be, completely free from
adverse reactions; yet decisions still must be made.' Should the pro-
duct be produced at all? Should the conditions under which it is to
be used be restricted? As long as human beings exist, mistakes in judg-
ment will be made occasionally. In that event, who is, or should be,
held liable?"
The attorney working in the field of products liability for drugs
and cosmetics needs certain basic factual information regarding the
drug or cosmetic involved in his particular case. Some of this infor-
mation is as follows:
1. Is the particular drug or cosmetic capable of producing the type
of reaction which occurred in the case?
* This article is adapted from a lecture delivered at the Institute on Personal Injury Liti-
gation held by the Southwestern Legal Foundation in Dallas, Texas, on November 5-6, 1964.
** M.D., University of Virginia School of Medicine; LL.B., George Washington Uni-
versity; Diplomate: American Board of Dermatology and Syphilology, 1955; Active staff:
Virginia Baptist Hospital and Lynchburg, Virginia, General Hospital; Consultant: Bedford
Memorial Hospital, Bedford, Virginia; Stonewall Jackson Memorial Hospital, Lexington,
Virginia; Southside Community Hospital, Farmville, Virginia; Medical Director, First Colony
Life Insurance Company, Lynchburg, Virginia; Member: Lynchburg Academy of Medicine,
American Academy of Dermatology, Virginia Bar Association; United States Public Health
Service, 1948-1951.
'See Ladimer & Newman, Clinical Investigation Medicine-Legal, Ethical, Moral As-
pects (1963).
'See Larrick, No Absolute Safety, NSA J. Am. Pharm. Ass'n 217 (1964).
'See 2 Frumer & Friedman, Products Liability § 28 (1964); 6 Lawyers' Medical Cyclo-
pedia §§ 45.7-45.8 (1958); Schwartz, Problems of Proof in Claims For Recovery For Derma-
titis, 41 Mich. L. Rev. 893 (1943).
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2. Was adequate pre-marketing testing of the drug or cosmetic
carried out, and were Food and Drug Administration require-
ments met?
3. With what frequency does the particular drug or cosmetic
produce reactions of the type occurring in the particular case,
and was the manufacturer aware of this incidence of reactions?
4. Did the particular drug or cosmetic in fact produce the un-
toward reaction?
5. Was adequate information regarding the use and safety of the
drug or cosmetic placed in the hands of the physician, patient
or consumer?
II. DRUG EVALUATION-PRE-MARKETING
New drugs generally are released to the market after thorough
scientific study and approval by the Food and Drug Administration
of the product itself, the materials used therein and the results ob-
tained in the scientific study regarding both toxicity and effectiveness.
The steps involved in pre-marketing scientific evaluation usually in-
clude the following:4
1. Chemical compounds are selected for laboratory study at ran-
dom or on the basis of their molecular structure, relating them
to other compounds of known pharmacological activity and
toxicity.
2. The chemical compounds are then tried on small laboratory
animals whose genetic and physiological patterns are known,
and the pharmacological and pathological results are assessed.
3. If the initial results are interesting in relation to the results
obtainable with known existing drugs, an elaborate series of
tests are conducted over a long period with a large number of
animals of various types and suitabilities. These tests involve a
study of the amount of the compound required to produce the
desired pharmacological or therapeutic effect and the amount
required to produce death of the experimental animals-thereby
establishing a margin of safety or tolerance. The structural and
functional effects of the drug on the liver, brain, blood, kidney
and all other organs are observed. The effect on the fetus during
pregnancy is studied, as is post-natal growth and development
during long-term administration of the drug.5
4. If the drug proves both to be safe and to have interesting thera-
4 Modell, Safety in New Drugs, 190 -J. Am. Med. Ass'n 141 (1964).
5 Commission on Drug Safety, Report on Conference on Prenatal Effects of Drugs (1963);
Drug Pairs Increase Teratogen Danger, Antibiotic News, Sept. 2, 1964, p. 3, cols. 1:3.
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peutic and pharmacological effects in animals, it remains to be
discovered whether it is safe and has similar effects in man.
5. If preliminary trials in normal human subjects show both safety
and the expected pharmacological effects, then the drug may be
tested in selected human cases of the pathological state which it
is expected to benefit.
6. If the initial human trials appear safe and rewarding thera-
peutically, the study is expanded to encompass hundreds or even
thousands of cases under rigid scientific controls over a period
of months or years.
7. If these extensive clinical trials are successful and if the drug
can be commercially produced and marketed satisfactorily, and
assuming the blessing of the Food and Drug Administration is
obtained, the drug reaches the open market and becomes avail-
able for use by physicians generally.
One of the primary purposes of drug evaluation prior to market-
ing is to detect any reactions which may result from the use of a
given drug under study. Some of the more serious types of reactions
which drugs may produce are set out below:
Table I: Types of Reactions to Drugs'
1. Allergic:
a. Anaphylactic shock and death
b. Generalized skin rashes
c. Serum sickness
2. Blood:
a. Aplastic anemia (failure to form white blood cells)'
b. Reduced white blood cell count (leucopenia)
3. Cardiovascular reactions:
a. High blood pressure
b. Low blood pressure
c. Peripheral vascular insufficiency
4. Endocrine-metabolic reactions:




b. Damage to the retina of the eye
c. Visual-function disturbances
"Year Book of Drug Therapy 1963-1964 Series, 495-617 (Beckman ed. 1964).
' Huguley, Agranulocytosis Induced by Dipyrone, a Hazardous Antipyretic and Analgesic,
189 J. Am. Med. Ass'n 938 (1964).
(Vol. 19:76
DRUG AND COSMETIC REACTIONS
6. Gastro-intestinal:
a. Intestinal ulceration and hemorrhage or perforation
b. Liver damage with jaundice
c. Pancreitus
7. Kidney:
a. Acute or chronic toxic kindey damage
8. Neurological:
a. Convulsive seizures




b. Intra-uterine death of the fetus or abortion
c. Post-natal respiratory distress
10. Psychiatric:
a. Drug addiction
b. Precipitation of psychotic or confusion states
III. DRUG EVALUATION-POST-MARKETING
Despite all of the precautions that are observed prior to marketing,
use of drugs both can and does result in unanticipated effects or reac-
tions after mass marketing. This is because the total picture regard-
ing the many effects which a given drug may produce becomes clear
only after an extended period of use by many thousands of patients.
We are constantly dealing with compounds which have increasing
biologic activity. These compounds are increasingly capable of pro-
ducing both desirable and undesirable effects.
Among other problems, a whole new list of genetic variations is
being discovered, including enzyme, chemical and hormonal abnor-
malities. Some of the persons whose abnormality is unknown to them
metabolize or handle certain drugs differently than the "normal"
person. These genetic differences account for some of the variations
in tolerances or reactions to drugs.'
Indispensable to an intelligent evaluation of a given drug after it
has been marketed, of course, is the availability of accurate statistics
on its actual performance, including the incidence of reactions pro-
duced by it. In this regard, certain characteristics of various types of
information-gathering systems are deserving of notice:
8 Analgesic Abuse and the Kidney-a Commentary, 190 J. Am. Med. Ass'n 238 (1964).
La Du, Pharmacogenetics, Oct. 26, 1964 (Unpublished, Symposium on Cutaneous Toxic-




Table II: Information-Gathering System Characteristics
1. Clinical statistics:
a. Hospital level:
Reflect only reactions occurring while in the hospital or
severe enough to require hospitalization; do not represent
a normal population cross section.
b. Office level:
Reflect only reactions occurring while under medical care
or severe enough to require medical attention; do not
represent a normal population cross section.
2. Industry statistics:
Reflect only reactions severe enough to mature into complaints
to the company; frequently available from only the individual
manufacturer.
3. Insurance statistics:
Reflect only reactions severe enough to mature into actual
claims.
4. Local or regional:
Difficult to correlate with drug or cosmetic distribution and to
determine incidence therefrom.
5. National:
National-level systems of any type are in their infancy.
Traditionally, both the drug and cosmetic industries have relied
largely on insurance-claim statistics and on industry complaint-file
statistics involving the incidence and types of reactions. The drug
industry, in addition to utilizing these sources, has also looked to
some local-area, clinical reaction-incidence statistics, but in the past
it generally has not aggressively sought out post-marketing reaction
information. With respect to drugs, however, a number of new
information-gathering programs have been instituted to provide a
better picture of the incidence of reactions at both the local and
national levels.' From the standpoint of the consuming public, the
ao (1) American Medical Association-Registry on Adverse Reactions.
a. Purpose:
To acquire and disseminate information on possible reactions to drugs which
had not been previously suspected, and serious reactions to any drug even if
they are known to occur; to evaluate the reports of adverse reactions to drugs
with the help of impartial experts; and to inform the profession promptly of
the nature and significance of reactions to potentially toxic drugs and other
agents.
Solicits reports from hospitals and individual physicians, and reviews 500-600




$35 North Dearborn Street
Chicago, Illinois 60610
(Continued on page 81)
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most important area is being undertaken for study first, because it
is in the drug area that the most severe reactions occur.
(2) Chemical-Biological Acitivities.





To provide a convenient key to all references concerning the biological activity






(3) Drug Information Center (Proposed) (Federation of American Societies for Ex-
perimental Biology, 9650 Wisconsin Avenue, Washington, D. C. 20014).
a. Purpose:
To establish by coordinated effort a drug-information clearing house to serve
government agencies, scientific groups, professional societies, trade associations,
universities and others.
b. Responsible Official:
Dean, College of Pharmacy
University of Minnesota
Minneapolis, Minnesota 55414
(4) Drugs iu Use.
a. Purpose:
Drugs in Use is a service offered to drug companies by Mr. Paul de Haen. To
provide in condensed and organized form references to significant drug data
taken from clinical observations and published in the literature. Covers (1)
single chemical entities, their salts and derivatives, including antibiotics and
enzymes, and also (2) combination drugs which are sold in the United States.
Abstracts from 199 Journals.
b. Responsible Official:
Mr. Paul de Haen
11 West 42d Street
New York, New York 10036
(5) Food and Drug Administration-Adverse-Reaction Reporting Program.
a. Purpose:
To obtain information promptly on the untoward effects of drugs (especially
newer drugs) from monthly reports received from participating hospitals. Until
1963 involved only 30 hospitals. Planned to include 1000 hospitals. Recent
agreement with American Medical Association to exchange information.
b. Responsible Official:
Director
Division of Research and Reference
Bureau of Medicine
Food and Drug Administration
Washington, D. C. 20025
(6) IPAD Working Group on Adverse Drug Reactions (Intergovernmental Procure-
ment Advisory Council on Drugs, Defense Supply Agency, Cameron Station,
Virginia).
a. Purpose:
To provide Food and Drug Administration with uniform reporting system of
adverse drug reactions from the medical facilities of the Army, Navy, Air
Force, Veterans Administration and Public Health Service.
b. Responsible Official:
Bureau of Medicine and Surgery
Navy Department
Washington, D. C. 20025
(Continued on page 82)
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IV. COSMETIC EVALUATION-PRE-MARKETING
New cosmetics and dermatological medicinals containing no ac-
tive therapeutic ingredients have been traditionally evaluated sci-
entifically in animals and man only for allergic sensitization capacity
and primary irritancy potential regarding the skin and eyes. The
Food and Drug Administration has usually required 200 human test
subjects.
(7) ISI Drug Alert.
a. Purpose:
To provide a weekly comprehensive listing to all published reports concerning
the clinical use of drugs. This listing is in the form of an index, arranged
alphabetically by trademark name or nonproprietary name. Cross reference be-
tween trade and generic name provided.
b. Responsible Official:
In-titute for Scientific Information
325 Chestnut Street
Philadelphia, Pennsylvania 19106
(8) Medical Literature Analysis and Retrieval System (MEDIARS).
a. Purpose:
Designed for use by the National Library of Medicine to perform various func-
tions of literature analysis and retrieval.
Provides abstracts covering 2,500 bioscience periodicals, of which sixty-five
per cent are in foreign languages.
b. Responsible Official:
Chief, Bibliographic Services Division
National Library of Medicine
Bethesda 14, Maryland
(9) Pharmacy Drug Information Services.
a. Purpose:
To enable pharmacists to be trained as drug-information specialists; to con-
tribute to rational drug therapy and to enable the pharmacist to serve the
physician as a "consultant" or "informant"; and to provide the means for
developing a plan to audit drug therapy in major teaching hospitals under a
program to improve the evaluation and use of drugs.
International Pharmaceutical Abstracts to cover 448 periodicals.
b. Responsible Official:
Executive Secretary
American Society of Hospital Pharmacists
2215 Constitution Avenue, N. W.
Washington, D. C. 20007
(10) Philadelphia Registry for Drug Reactions (Greater Philadelphia Committee for
Medical-Pharmaceutical Sciences, 3401 North Broad Street, Philadelphia, Penn-
sylvania 19140).
a. Purpose:
To establish a metropolitan drug-reaction registry that could serve as a model
for other cities, and to collect "meaningful information" from the five teaching
hospitals in Philadelphia.
b. Responsible Official:





This service is an outgrowth of the Documentation Ring set up by a group of
pharmaceutical companies in Europe to supply their need for information about
new drugs. To provide in abstract form references to articles of pharmaceutical
interest, including pharmacologic as well as clinical reports. The abstracts cover
a wide range of subjects.
(Continued on page 83)
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The cosmetic industry today, however, with its constant striving
for enhanced cosmetic values, has embarked to a considerable degree
upon the development of cosmetics which "do something" from an
aesthetic, therapeutic or prophylactic standpoint."1 Moisturizers, dry-
ing agents, bleaches, dyes, hormones, bacteriostatic agents, antibiotics,
vitamins and other ingredients of an "active" nature are being added
to cosmetics. This trend, of course, begins to require testing not only
for toxic and harmful effects locally to the skin, but also for systemic
absorption through the skin and for therapeutic effectiveness.'
A. Predictive Testing Of Cosmetic And
Dermatologic Pharmaceuticalsa
There are no tests that absolutely guarantee safety. This question
can be resolved only after sufficient trial by many users over a long
period. Predictive procedures in their present form are imperfect
tools. At best, they can only be considered as rough screening devices
which can idntify the "bad actors," either irritants or sensitizers.
Predictive tests may be falsely negative or falsely positive. In false
negative tests, the product passes the test, but trouble is encountered




Rochdale House, Theobalds Road
London, W. C. 1, England
(12) Scientific Group on the Evaluation of the Safety and Efficacy of Drugs (World
Health Organization, Geneva, Switzerland).
2. Purpose:
To collect information concerning the safety and efficacy of new drugs as they
are introduced from national health authorities in member countries. No
clearing-house for such information has been established, but data is apparently
becoming available on a limited basis directly from cooperating nations.
b. Responsible Office:
Division of Biology and Pharmacology
World Health Organization
Geneva, Switzerland
A detailed compilation of current adverse drug-reaction reporting programs is
available on request from the Pharmaceutical Manufacturers Association, Wash-
ington, D. C.
Certain inherent differences between drugs and cosmetics are worthy of note:
Drugs: Taken for relief of pain, discomfort or disease under medical supervision. When
is the risk of reaction worse than the disease being treated? What is the permissible reaction
rate?
"Over-the-counter" drugs: Taken for relief of pain, discomfort or disease. No medical
supervision. Permissible reaction rate?
Cosmetics: Used for beautification. No disease relief involved. No medical supervision.
Reaction rate permissible? Reaction rate that will interfere with sales?
" LeVan, The Cosmetic Industry and the Clinical Investigator, The Evaluation of Thera-
peutic Agents and Cosmetics 142-49 (Sternberg & Newcomer eds. 1964); Conley, Toxicity
Problems of Cosmetics, 166 J. Am. Med. Ass'n 638 (1958).
a Rostenberg, Predictive Procedures for Eczematous Hypersensitivity, 20 A.M.A. Ar-
chives of Industrial Health 181 (1959).
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cause of inappropriate sampling or inaccurate conclusions from the
data. The false positive test, on the other hand, means that the ma-
terial causes trouble under the conditions of testing, but not under
use conditions. False positives arise because of inappropriate biological
techniques.
The two independent variables in predictive testing are the biologi-
cal and the statistical variables. By the biological variable is meant the
degree to which the predictive technique fails to simulate the con-
ditions under which the product will be used. Included in the statisti-
cal variable are two somewhat independent questions, namely: (1)
How much confidence can one have that the outcome of the given
experiment was not due to chance alone? (2) What extrapolations
can be made from the results on the test sample to the larger universe
of potential users?
With regard to the biological variable, it appears obvious that for
the predictive technique to simulate use conditions, at least two
factors must be controlled: (1) The population on which the test is to
be conducted must be reasonably representative of the population for
whom the product is designed, and (2) the conditions under which
the test is applied must be a reasonable facsimile of the conditions
under which the product will be used. It is at times very difficult and
sometimes impossible to control the second factor. This does not
imply that predictive procedures should not be used, but it does
emphasize that the further the divergence between the predictive
techniques and the use conditions, the less confidence one can have
in the prediction. For example, the limitations of predictive tech-
niques with respect to the projection of results of patch tests on the
relatively limited numbers of the patch-test group to the larger
numbers of potential consumers are not well appreciated.1'
14 These limitations are shown by the following table:
Statistical Calculations: Maximum Anticipated Reactions in General Public From Analysis
of Prophetic Patch-Test Data:
Per Cent Anticipated Reactions in General Public
Test Population Per Number of Positive Reactions in Test Population
(Sample Number None One Two
of Individuals) (Per Cent) (Per Cent) (Per Cent)
30,000 0.01 ... .
10,000 0.03 0.05 0.06
5,000 0.06 0.09
1,000 0.3 0.45 .
200 1.5 2.2 2.9
100 3.0 4.4 5.8
so 5.8 8.8
20 13.9 20.8 27.0
10 26.9 38.2 ...
See Spoor, Skin Reaction to Cosmetics--Classifications and Diagnosis, 60 N.Y. State J. Med.
1940 (1960).
[Vol. 19:76
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Conventionally, statisticians employ the ninety-five per cent and
the ninety-nine per cent confidence levels. If 200 persons are tested
and no reactors are found in the challenge test, it is not likely that
more than fifteen reactors will be encountered out of every 1000
persons using the material. By the phrase "with a ninety-five per
cent likelihood" it is meant that, if, for example, 100 groups
of 1000 persons each used the material, in ninety-five of the groups
there would be fifteen or fewer reactors, but it is possible that in five
groups there would be more than fifteen reactors. In a similar manner,
the likely number of reactors could be computed at a ninety-nine
per cent confidence level, meaning that the prediction would likely
be wrong only once in 100 times.
If a manufacturer wished to be certain that he would not encounter
more than one reactor out of every 1000 users and he wished to
predict this result at a ninety-five per cent confidence level, a sample
of 3,000 individuals would be required with no positives. Such a
sample, however, would not ordinarily be feasible, from the stand-
point of either the cost to the manufacturer or the facilities and test
population available to the average investigator.
Most of the testing procedures currently in use are oriented toward
the two variables mentioned above (biological and statistical). Thus,
they are designed to simulate closely use conditions and to result in
a high degree of statistical veracity. Some of these testing procedures
are described in the margin."5
" Predictive Testing Procedures Commonly Employed Today for Cosmetics or Drugs
To Be Applied to the Skin
(1) Landsteiner guinea-pig test:
a. Subject-white male guinea pig, weighing 300-450 gm.
b. 0.1 per cent solution of suspension in saline injected in subject intracutan-
eously.
c. Injection made every other day or three times a week until ten have been given.
d. First injection-0.05 ml. solution; subsequent injections-0.1 ml. solution.
e. Injections made in a 3-4 cm. area on upper back or flank.
f. Readings made after each of the ten injections.
g. After tenth injection, two weeks' rest.
h. Final test conducted with 0.05 ml. solution.
i. Comparison of average of first ten readings with eleventh reading.
(2) Draize human technique:
a. 200 persons (100 men, 100 women) of a wide age range.
b. 0.5 ml. or 0.5 gm. applied by patch to arms or back.
c. Patch removed after twenty-four hours, and site read.
d. Rest for twenty-four hours.
e. Patches repeated until ten have been made; areas randomized.
f. Ten to fourteen days of rest.
(3) Schwartz-Peck human technique:
a. Standard patch test for forty-eight hours, with use of both the new and old
formula on 200 subjects.
b. Site read for three days.
c. Rest period of ten days.
d. Repeat standard patch test with both formulae.
(Continued on page 86)
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In light of this background, a relatively safe pre-marketing test-
ing procedure has been suggested. The procedure outlined below is
designed to produce statistics that form an adequate basis for valid
predictions concerning the incidence of reactions; to meet the re-
quirements of the Food and Drug Administration; and, at the same
time, to be feasible for the manufacturer with limited funds and
facilities.
An outline of a possible pre-marketing testing program is as
follows:
1. Closed patch test: forty-eight hours, 200 subjects.
2. Use accepted comparable product for control testing.
3. Read tests on third, fourth and fifth days.
4. Repeat tests on same subjects ten to eighteen days later.
5. Use tests (paired comparison) with old and new products-
same subjects, daily for one month.
6. If no dermatitis: trial sale of 5,000 to 10,000 packages in one
community during one month.
7. If one case of dermatitis: retest on 200 new subjects.
8. Even if no reactions in 30,000 subjects, reaction rate of 0.01
per cent is likely-no tests guarantee safety.
Two hundred subjects is the minimum control group generally ac-
cepted by the Food and Drug Administration in line with its policy
of requiring testing adequate to make statistically valid predictions
as to the probable incidence of reactions when the product is dis-
tributed to the general public. Trial sale of 5,000 to 10,000 units of
the drug is suggested in order to verify predictions made on the basis
of the patch tests under conditions that closely simulate sale to the
general public. If one reaction occurs, further tests are indicated;
thus, in that event, retesting on 200 new subjects is suggested.
A relatively new technique has been under development for several
years by Drs. Albert Kligman and William L. Epstein"6 for patch
e. A use test for four weeks by the same 200 persons with both formulae on
opposite sides of the body.
(4) Shelanski-Shelanski human technique:
a. Standard patch test for twenty-four hours.
b. Rest for twenty-four hours.
c. Repeat steps a and b, using same sites for fifteen applications.
d. Rest for two to three weeks.
e. Standard patch test for forty-eight hours.
(5) Traub-Tusing-Spoor human technique (combined patch and use test):
a. Initial patch.
b. Three-week use test on appropriate subjects.
c. Two weeks' rest.
d. Challenge patch.
s Kligman, Calnan & Epstein, Methods of Evaluating Contact Sensitizers, The Evalua-
tion of Therapeutic Agents and Cosmetics 157-70 (Sternberg & Newcomer eds. 1964).
[Vol. 19:76
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testing, prior to marketing, for cutaneous irritancy and sensitivity
with a much smaller number of individuals than the 200 persons
currently required by the Food and Drug Administration. This test
makes no attempt to reproduce use conditions, but pushes the toler-
ance for the drug or cosmetic to the worst possible cutaneous ex-
posure and demonstrates what the compound may do under the most
unfavorable circumstances. It provides a maximization of potential
situations likely to be encountered, and it is felt that a compound
can be initially assessed regarding its irritating or sensitizing capacity
with the use of about twenty-five subjects.
Dr. Kligman's technique, simplifid to its basic elements, includes
irritating the skin initially in one of several possible ways. Most re-
cently he has stabilized on the use of sodium lauyrl sulfate, although
satisfactory irritation can be produced by ultra-violet light or by
slight freezing of the skin surface. The patch test is then applied to
the irritated skin and covered with an occlusive plastic film.
Paraphenylenediamine under these circumstances will sensitize
twenty-five out of twenty-five, and so will the insecticide malathione.
Nevertheless, both of these compounds have been used extensively
with nothing like the disastrous results suggested, because the actual
use conditions are substantially different from those of the test con-
ditions.
Substances which show no reactions with Dr. Kligman's maximi-
zation technique would necessarily have to be rated as compounds
which have substantially less capacity to irritate or sensitize than
those showing twenty-five reactions out of twenty-five. This system
perhaps provides a grading standard of sorts for various classes of
compounds and their potential irritancy or sensitization capacity.
C. Types Of Cosmetic Reactions And Their Usual Causes"
Use of various cosmetics can cause a variety of allergic reactions."
The most common allergic reactions to cosmetic products are of the
1 Dermatoses due to Environmental and Physical Factors, 206-24, (Rees ed. 1961)
(hereinafter referred to as Rees); Kinmont, Skin Reactions to Cosmetics Preparations, 15
J. Soc'y Cosm. Chem. 3 (1964).
as In the following table, there appears information concerning reactions to and other
characteristics of various cosmetics and related products.
(1) Soaps and Detergents
1. Not cosmetics in legal sense.
2. 4.5 billion pounds used in United States during 1954 (seventy-five per cent
detergents).
3. Defatting and dehydrating.
4. Allergy is rare.
5. Common allergies caused thereby-"housewives' eczema," "winter itch."
6. Dry skin is irritable and vulnerable.
7. Aggravates dry and senile skin, atopic and contact dermatitis.
8. Keratin water loss is vital.
tContinued on page 88)
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dermatitis variety. Apparently the incidence of this type of reaction
is even more common than reports indicate. Dermatitis can arise from
Rees, op. cit. supra note 17, at 211; Suskind, Cutaneous Effects of Soaps and Synthetic
Detergents, 163 J. Am. Med. Ass'n 943 (1957).
(2) Hair Dyes
1. May cause dermatitis (local and general), occular disturbances, pain, headache.
2. One and one-half per cent sensitive on first exposure; two and one-half per
cent sensitive on total exposure.
3. Least likely to cause reaction-synthetic coal-tar dyes (paraphenylenediamine
and paratolylenediamine).
4. More likely to cause rcaction-vcgetable and heavy-metal dyes.
S. Food and Drug Administration restrictions-patch test each time; forbidden
near eyes.
6. "Rinse"-a euphemism.
Rees, op. cit. supra note 17, at 212; Committee on Cosmetics of AMA, 27 Hygeia 318, 354
(1949).
(3) Cold Permanent Waving
1. Involves physical, chemical and morphologic changes.
2. Alkaline (usually ammonium) salts of thioglycolic acid.
3. Surface-active agent also (allergy).
4. Gums and resins (clouding agents).
5. Perfumes and coloring (allergy).
6. Neutralizers (peroxides, perborates, bromates, citric acid).
7. Usual reaction: alkali burn.
8. Remarkably safe (if used properly).
Rees, op. cit. supra note 17, at 214; Lehman, Health Aspects of Common Chemicals Used
in Hair-Waving Preparations, 141 J. Am. Med. Ass'n 842 (1949).
(4) Depilatories
1. Types:
a. Calcium thioglycolate (four to ten per cent) cream; newest, most popular-
softens keratin.
b. Sodium or calcium salfide (acts like thioglycolate).
c. Waxes.
d. Electrolysis.
e. Others (mercaptans, xanthates).
2. Direct irritation or infection.
Rees, op. cit. supra note 17, at 215-16; Schwartz, Tulipan & Birmingham, Occupational
Diseases of the Skin (1957).
(5) Face Creams
1. Many ingredients (including hormones, bleaches, etc.).
2. Most common offenders-perfume, alkalinity, emulsifying agents or oil-phase
ingredients.
3. Dermatitis is rare.
Rees, op, cit. supra note 17, at 215-16; Schwartz, Tulipan & Birmingham, Occupational
Diseases of the Skin (1957).
(6) Deodorants
1. Most common ingredients-aluminum chloride, sulfate, and phenolsulfonate
(mild antibacterial).
2. Deodorant soaps-hexachlorophene ("Phisohex," "Dial"), tetramethylthiura-
midisulfide ("Lifebuoy"), actamer or bithionol (similar to hexachlorophene)
antibacterial.
3. Others: antibiotics (Neomycin), oxidizers, bcnzoic acid, hexamine, oxyquiso-
nine-antibacterial.
4. Antiperspirant-none?
5. Most likely reactions: retention cysts, furuncles and irritation.
6. Dermatitus not uncommon.
7. Possible cross-sensitivity with inhibitors in rubber and fabric-tetramethyl-
thiuramdisulfide.
8. Antibiotic sensitivity-rare.
P. Zirconium salts--granulomas (rare).(Continued on page 89)
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three different mechanisms: (1) acquired allergy, which is the most
common mechanism; (2) chemical or physical irritation; and (3)
Rees, op. cit. supra note 17, at 215-16; Schwartz, Tulipan & Birmingham, Occupational
Diseases of the Skin (1957).
(7) Neomycin: Dermal Delayed Sensitivity
1. Used as deodorant and preservative.
2. Patch tests often negative.
3. Intradermal test: 0.05 ml., 1:1000 or 1:00 solution.
4. Popular reactions-forty-eight hours.
5. Controls negative.
6. Apparently rare (ten cases reported).
Rees, op. cit. supra note 17, at 217; Epstein, Contract Dermatitis From Neomycin Due to
Dermal Delayed (Tuberculin-type) Sensitivity-Report of Ten Cases. 113 Dermatologica
191 (1956).
(8) Zirconium Deodorant Granulomas
1. Rare but important.
2. Protracted and disabling.
3. Allergic granulomas.
4. Intradermal tests positive (1:1000 to 1:10,000 solution).
S. Criteria of allergy fulfilled (rare, delayed, weak concentration, controls nega-
tive).
Rees, op. cit. supra note 17, at 217; Shelley & Hurley, The Allergic Origin of Zirconium
Deodorant Granulomas, 70 Brittish J. Dermatology 75 (1958).
(9) Hair Tonics and Lotions
1. Frequently cause dermatitis.
2. Usually contain antiseptic, rubifacient, oil, perfumed alcohol.
3. Resorcinol, betanaphthol, salicylic acid, capsicum and cantharides are both
sensitizers and primary irritants in sufficient strength.
4. Wetting agents (sodium lauryl salfate, triethanolamine) may sensitize.
S. Perfumes may cause trouble.
6. Newer commercial anti-seborrheic shampoos (e.g., sulfides, hydroxy quinolines)
may be irritating.
Rees, op. cit. supra note 17, at 218; Schwartz, Tulipan & Birmingham, Occupational
Diseases of the Skin (1957).
(10) Suntan Preparations
1. PABA (paraaminobenzoic acid) and esters.
a. Direct sensitization (Baer and Melzer).
b. Cross-sensitivity (PPDA, aniline dyes, sulfa, local anesthetics).
a. Photosensitization (Satulsky).
2. Common ingredients-digalloyl trioleate, menthyl salicylate and anthranilate,
and many others.
3. Psoralens abused (suntan pills).
a. Furocoumarin-parsnip, celery.
b. Photodynamic absorption (?).
c. Thick horny layer and increased pigment.
d. Carcinogenic (?).
Rees, op. cit. supra note 17, at 219; Sagarin, Cosmetics: Science and Technology (1957);
Becker, Use and Abuse or Psoralens, 173 J. Am. Med. Ass'n 1483 (1960).
(11) Perfumes
1. Found in most cosmetics.
2. Three chief sources: vegetable, animal (ambergris and musk) and synthetic.
3. Complete composition (alcohols, terpenes, aldehydes, esters, ketones, phenols,
acids, anhydrides, nitrogenous substances, hydrocarbons).
4. Contact penetration and exposure to light of required wave length.
5. Essential oils (penetrate keratin easily).
6. Common offenders: oil of bergamot (berlock dermatitis), methyl heptine, car-
bonate (synthetic violet and jasmine), and linalool (a terpene alcohol).
7. Fairly common offenders (photosensitizers).
Rees, op. cit. supra note 17, at 219; Schwartz, Tulipan & Birmingham, Occupational
Diseases of the Skin (1957). (Cntnue on page 90)
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photosensitivity.'" A full appraisal of the patient's medical history is
the key to diagnosis, but a "re-use" test or patch test is used to con-
firm the preliminary diagnosis."0
For convenience, the most important types of tissue reactions and
their usual causes are set forth below in tabular form.
Table III: Types of Tissue Reactions to Cosmetics'
1. Dermatitis (irritative and/or allergic).
Usual cause: lotions, dyes, perfumes, creams, powders, lac-
(12) Skin Lighteners and Bleacbers
1. Mercury (ammoniated five per cent or chloride 0.5 per cent).
a. Used for centuries.
b. Temporary lightening only.
c. Qualified approval by Food and Drug Administration.
d. Discoloration from prolonged use.
e. "Poisons" (?)-tyrosine, tyrosinase.
f. Irritant and sensitizer.
2. Zinc peroxide anhydrous ointment.
3. Monobenzyl-etber of hydroquinone-five per cent lotion, twenty per cent cream
(capricious).
4. Ascorbic acid (ineffective and unstable).
Rees, op. cit. supra note 17, 221; Sagarin, Cosmetics: Science and Technology (1957).
(13) Lipstick and Cheilitis
1. Dermatitis (cheilitis) is usually from perfume or dye.
2. Not uncommon.
3. Hypersensitivity (allergy).
4. All dyes must be FDA-approved.
. Fluorescent dyes (halogen derivatives of fluorescein) penetrate and photo-
sensitizers.
6. Negative lipstick patch tests may become positive after sun exposure.
Rees, op. cit. supra note 17, at 219; Schwartz, Tulipan & Birmingham, Occupational Dis-
eases of the Skin (1957).
(14) Nail Preparations
1. Most common reaction-patchy dermatitis of face and neck.
2. Chiefly caused by resin content of nail lacquer.
3. Sixteen principal types of synthetic resins.
4. Most common offender-sulfonamide-formaldehyde resin.
5. FDA-certified dyes may cause trouble (fluorescent dyes include eosin, erythrosin,
fluorescein, and rhodamine B; nonfluorescent offenders include Lithol red,
Methanil yellow, Bordeaux red, and Alizarine).
6. Dry brittle nails-lacquers, removers, soaps, detergents.
7. Destructive changes-resins, acrylics.
Rees, op. cit. supra note 17, at 222; Schwartz & Peck, Cosmetics and Dermatitis (1946);
Sutton, Diseases of the Skin (11th ed. 1956).
19Allergic Contact Dermatitis-Definition
1. Incubation period necessary (five days or more).
2. Sensitivity becomes generalized.
3. Substance reacts in weak concentration.
4. Patch test positive on distant sites.
5. Patch test negative on control subjects.
6. Sun exposure also necessary in photoallergy.
7. Hyposensitization or tolerance often occurs spontaneously.
Rees, op. cit. supra note 17, at 210; Schwartz & Peck, Cosmetics and Dermatitis (1946).
20 Rees, op. cit. supra note 17, at 209; Nelson, Clinical Appraisal of Dermatoses Due to
Cosmetics, 163 J. Am. Med. Ass'n 740 (1957).
"' Rees, op. cit. supra note 17, at 206; Spoor, supra note 14.
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3. Hair damage; conjunctivitis.
Usual cause: alkalis (e.g., hair wavers, straighteners),
bleaches, shampoos.
4. Local swelling.
Usual cause: hormone cream.
5. Nail damage.
Usual cause: base coat (formaldehyde resin), nail builders
(acrylics).
6. Photosensitivity.
Usual cause: suntan agents, perfumes, lipstick dye.
7. Pigment changes.
Usual cause: mercury, hydroquinone, perfumes (post-
inflammatory).
8. Sweat-gland abscesses; granulomas.
Usual cause: aluminum salts, zirconium salts.
V. POST-MARKETING PERFORMANCE OF COSMETICS
Unlike the drug industry, the cosmetic industry has not yet initi-
ated large-scale, information-gathering programs. It largely has relied
on insurance-claim and industry complaint-file statistics involving
the incidence and types of reactions to evaluate the post-marketing
performance of its products.
An analysis of certain of these statistics provides some basis upon
which to quantify the incidence of allergic reactions to cosmetic
preparations. For example, Dr. Rees has published data concerning
the incidence of reactions to the marketed products of one large
cosmetic manufacturer."2 The figures are of the complaint-file type.
Dr. Rees indicates that a total of 448 reactions (0.0004 per cent)
were reported out of sales of 113 million units of 150 different cos-
metic products. Almost fifty per cent (236) of the reactions were
caused by depilatories, lotions or eye products. The incidence of
reactions to the use of cleaners, creams, shampoos, hair rinses and de-
odorants was significantly lower. Reactions to wave lotions, powders,
lipsticks and perfumes were the least common. No reactions from
use of nail polish were reported. The incidence of reactions to the
2 Rees, op. cit. supra note 17, at 207; Masters, Allergies to Cosmetic Products, 60 N.Y.
State J. Med. 1934 (1960).
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various products as reported by Dr. Rees is set forth in the margin.'"
Robert Goldemberg compared Shulton consumer irritation-com-
plaint statistics to unit sales by the cosmetic industry. He reported
that, on an industry-wide basis, from 1957 to 1961 there was an
average of .204 consumer complaints of reactions per 100,000 units
sold. Approximately .065 complaints per 100,000 units sold were of
such a nature that the complainant required medical attention. These
statistics are presented by product class in the table in the margin."
In addition to the basic lack of source material, there exists a wide
statistical variation among the various sources of information which
currently are available. To illustrate this statistical variation, a survey
made by Dr. F. Reiss"3 may be compared with the number of reported
23 Reported Freouency of Reactions To 113 Million Units of Cosmetics Sold
AGENT % AGENT %
Depilatories 0.004 Hair Products 0.0003
Cleansers 0.002 Shampoos 0.0002
Wave Lotions 0.001 Make Up 0.0001
Hormone Creams 0.001 Powders 0.00007
Lotions 0.0005 Medicated Creams 0.00005
Eye Products 0.0005 Suntans 0.00005
Creams 0.0004 Lipstick 0.00002
Deodorants 0.0003 Colognes and Perfumes 0.00002
Rinses 0.0003 Nail Polish 0.00000
Rees, op. cit. supra note 17, at 208; Masters, supra note 22.
24 Comparison of Shulton Consumer Irritation--Complaint Rates to Unit Sales
Unit Sales Allergic Reactions per 100,000 Units Sold
5 yrs. Total Required Med. Att'nProduct Category (millions) 1961 5 yrs. 1961 (per 5 yrs.)
Alcoholic perfumes 100 0.037 0.043 -0- 0.018
Antiperspirant 10-20 0.340 0.350 0.034 0.110
Bath products 10-20 0.033 0.023 -0- 0.006
Deodorants 20-50 0.282 0.464 0.060 0.174
Emulsions, general 10-20 0.110 0.087 0.022 0.019
Hair, general 5-10 0.044 0.051 0.044 0.025
"Medicated" items 1-5 2.408 5.577 0.230 0.908
Shaving products 20-50 0.122 0.118 -0- 0.021
Sunscreens 5-10 1.323 0.729 0.265 0.307
OVERALL RATES* 275 0.204 0.065
Goldemberg, Cosmetics and the General Population-Safety Aspects, Proceeding of he
Scientific Section, No. 38, The Toilet Goods Ass'n (1962).
* Note: Of the 560 irritation complaints received in the five-year period 1957-1961, 129
resulted from the "medicated items category." Omitting these 129 complaints, the overall
irritation rate for the purely cosmetic and toiletries items drops from 0.204 to 0.157 per
100,000 units sold.
" Tabulation and Analysis of Replies to Questionnaires Sent by Dr. F. Reiss
to 2969 Dermatologists in 1958
No. of Per Cent No. of Cases per
Cases of Total Physician Reporting
Permanent Wave Lotion 3764 25.2% 3.9
Lipstick 2137 14.4% 2.2
Hair Dye 3549 23.8% 3.7
Nail Lacquer 5447 36.6% 5.7
Total 14,897 100% 15.5
Reiss, Cosmetic Dermatitis-A Survey of Its Incidence, 116 Dermatologica 419 (1958).
(Continued on page 93)
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insurance claims through the National Bureau of Casualty Under-
writers."











































Number of Positive Cases
M. Lip- Hair Nail
ve stick Dyes Lacquer
4 650 1370 1627
7 254 462 813
6 247 424 739
6 285 424 732
'7 145 287 315
2 354 287 664
9 128 170 204
'3 84 125 353
Reiss, Cosmetic Dermatitis-A Survey of Its Incidence, 116 Dermatologica 419, 422 (1958).
Replies were received from only 956 of the 2969 Dermatologists to whom questionnaires
were mailed.
Sales figures in dollars for the above cosmetics for 1956, as published in the Drug
Trade News of August 12, 1957, can be related to the number of units sold. It should be
noted, however, that units of nail lacquer and lipstick are repeatedly used, whereas hair
dyes and permanent waves represent packages used only once. The values in dollars were:
Home permanents and refills $86,510,000
Hair tints and dyes $20,670,000
Lipsticks $71,330,000
Nail polish and enamel $26,170,000
2Products-Liability Insurance Claims
Policy Sales of Covered Entities Number of
Year Indemnity Claims





















Total $1,334,3 14,000 1,330








(Continued on page 94)
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Dr. F. Reiss' survey reflects replies from about one-third of the
skin specialists in the nation in 1958. This survey shows 14,000
reactions in 1958 to a limited number of cosmetic preparations.
In contrast, the number of insurance claims during that year was
less than 1,000 for a large number of products, including all those
covered by Dr. F. Reiss' survey. The actual number of cases, however,
must have numbered between 15,000 and 50,000, considering that
many consumers must have sought either medical advice from non-
specialists or no medical advice at all.
Thus, it appears that in the cosmetic field the testing procedures
currently in use are not entirely adequate. Furthermore, the Food
and Drug Administration does not impose as stringent requirements
on that industry as it does upon the drug industry. Moreover, the
evaluation of cosmetic products is complicated by the dearth of sta-
tistics concerning post-marketing performance and by the wide sta-
tistical variation among the various sources of information that are
available.
These apparent deficiencies, however, do not necessarily mean that
the cosmetic industry has failed to engage in thorough testing pro-
cedures before marketing new products. There are some checks and
balances in the cosmetic field. The major manufacturers who sell
products nationally on a large scale simply cannot afford to take
chances on a new product. In contrast to drugs, the cosmetic must
have direct consumer patronage and acceptance. Bad reputation from
just one product can affect sales of all other products on which sur-
vival as a profitable corporation depends. From a commercial point
of view, it would be a self-defeating proposition for these corpora-
tions to sell a product which they knew to be harmful to the public
in any way. Aside from the ethics and the question of corporate repu-
tation, the manufacturers must also consider "product liability" in-
surance rates. For these excellent economic reasons, thorough safety
testing of new products is conducted by nearly every major corpora-
tion in the cosmetic field, as well as by most smaller ones.
National Bureau of Casualty Underwriters-unpublished statistical data (1956-60).
* Included in this class are the following: face, toilet, bath and baby powder; rouge
and lipstick; toilet water and bath salts; finger nail and toenail cream or polish; cuticle
or polish remover; facial packs; hair tonics; creams or lotions other than specific-purpose
creams or lotions.
**This classification includes but is not limited to hair rinses or packs, hair dyes,
depilatories, skin bleaches, freckle removers, deodorants, reducing creams, eye shadow, eye-
brow pensil, mascara, hair bleach and suntan lotion.
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